Skip to content

RVL Pharmaceuticals plc

CIK 0001739426

← back to feed
Revenue (TTM)
$35.56M
+184.1% YoY Q2 Aug 2023
Net Income (TTM)
−$62.05M
+20.4% YoY Q2 Aug 2023
EPS Diluted (TTM)
−$0.66
+39.6% YoY Q2 Aug 2023
Gross Margin
74.7%
Q2 Aug 2023
Operating Margin
-172.5%
Q2 Aug 2023
Net Margin
-174.5%
Q2 Aug 2023
Free Cash Flow (TTM)
−$33.35M
Q2 Aug 2023
Cash
$19.16M
Q2 Aug 2023
Total Debt
$121.35M
Q2 Aug 2023
Shares Outstanding
99.54M sh
Q2 Aug 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings